Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
BUSINESS
Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
Mitsubishi Chemical Group has upwardly revised its annual earnings forecast for the year ending March 2023 after a decision in favor of the company in arbitration proceedings over royalty payments tied to the multiple sclerosis drug Gilenya (fingolimod). According to…
To read the full story
Related Article
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
- Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
February 15, 2023
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
BUSINESS
- Nxera Unveils Proprietary Pipeline Targeting Obesity and Weight Management
August 7, 2025
- Nippon Zoki Snags Japan Rights to Kagoshima University Offshoot’s Oncolytic Virus
August 6, 2025
- Eisai Sees Subcutaneous Autoinjector as Key to Boosting US Demand for Leqembi
August 6, 2025
- Takeda Taps AI Demand Forecasting for 70% of Products, Aims to Bolster Supply Reliability
August 6, 2025
- Sumitomo Files iPS Cell-Derived Dopaminergic Progenitor Cells in Japan
August 6, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…